General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, and Forms FDA 356h & 2567
ICR 200507-0910-004
OMB: 0910-0338
Federal Form Document
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0910-0338 can be found here:
General Licensing Provisions:
Biologics License Application, Changes to an Approved Application,
Labeling, Revocation and Suspension, and Forms FDA 356h &
2567
Extension without change of a currently approved collection
The PHS Act and FDA regulations
require manufacturers to submit a license application for review
and approval prior to marketing a biological product in interstate
commerce. Manufacturing must also submit to FDA supplementals to an
approved application, and advertising and promotional labeling.
There are also requirements regarding suspension and revocation of
a license.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.